Viewing Study NCT00036764



Ignite Creation Date: 2024-05-05 @ 11:25 AM
Last Modification Date: 2024-10-26 @ 9:07 AM
Study NCT ID: NCT00036764
Status: COMPLETED
Last Update Posted: 2013-01-25
First Post: 2002-05-13

Brief Title: BMS-247550 in Treating Patients With Stage IV Melanoma
Sponsor: National Cancer Institute NCI
Organization: National Cancer Institute NCI

Study Overview

Official Title: A Phase II Study Of Epothilone B Analog BMS 247550 NSC 710428 In Stage IV Malignant Melanoma
Status: COMPLETED
Status Verified Date: 2013-01
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have stage IV melanoma Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die
Detailed Description: OBJECTIVES

I Determine the efficacy of BMS-247550 in patients with stage IV melanoma II Determine the toxicity of this drug in these patients

OUTLINE This is a multicenter study Patients are stratified according to the number of prior chemotherapy regimens 0 vs 1-2 including dacarbazine or temozolomide

Patients receive BMS-247550 IV over 1 hour on days 1 8 and 15 Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
NYU-0057 None None None
N01CM17103 NIH None None
CDR0000069320 REGISTRY PDQ Physician Data Query httpsreporternihgovquickSearchN01CM17103